Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. Its primary product, Endari, is FDA-approved for sickle cell disease, reducing crises and hospitalizations. The company operates through licensing, distribution, and strategic partnerships, targeting global markets with a focus on innovative therapies, including cell sheet technology and cancer treatments, emphasizing safety, efficacy, and regulatory compliance.
This description was generated via AI from an annual report. Updated about 1 year ago.